molecules of the month

compound 23

oral CAT K inhibitior

reduced uCTX-I levels in dog model

from opt of a previously disclosed cmpd

Bioorg. Med. Chem. Lett.

Merck, West Point, PA

compound 23 chemical structure oral CAT K inhibitior - Merck, West Point, PA
4 mins read

Context. “Compound 23” (Merck) is a selective oral cathepsin K (CatK) inhibitor intended for osteoarthritis.  Osteoarthritis affects around 15% of the population, and current treatments offer only symptom relief, highlighting the need for targeted treatments. Prior to the “compound 23”, several CatK inhibitors had reached clinical development: relacatib (GSK), balicatib (Novartis), ONO-5334 (Ono Pharmaceuticals), and odanacatib (Merck). Merck’s preclinical compound MK-1256 was only 40-fold selective, so they set out to develop a compound with at least 1000-fold selectivity for CatK over other biologically relevant cathepsins, using MK-1256 as a starting point.  Target. CatK is a dimeric collagen-degrading cysteine protease and plays a key role in bone resorption by osteoclasts. Upregulation of the enzyme has been observed in articular cartilage of…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: